Jupiter Neurosciences (JUNS) Convertible Debt (2023 - 2024)
Jupiter Neurosciences (JUNS) posted quarterly Convertible Debt of $121725.0 for Q3 2024, up 14.07% quarter-over-quarter from $106712.0 in Q4 2023.
Jupiter Neurosciences (JUNS) Convertible Debt (2023 - 2024) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Convertible Debt for 2 consecutive years, with $121725.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Convertible Debt changed N/A year-over-year to $121725.0; the TTM figure through Sep 2024 stood at $121725.0 (changed N/A YoY), while the FY2023 annual figure was $106712.0, changed N/A from the prior year.
- Convertible Debt grew to $121725.0 in Q3 2024 per JUNS's latest filing, from $106712.0 in the prior quarter.
- Across five years, Convertible Debt topped out at $121725.0 in Q3 2024 and bottomed at $106712.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 121,725.00 |
| Dec 31, 2023 | 106,712.00 |